As per DelveInsight, the Retinal Vein Occlusion therapeutics market is anticipated to evolve immensely in the coming years owing to the expected launch of potential therapies and an increase in the diagnosed prevalent population of Retinal Vein Occlusion.
“Retinal Vein Occlusion Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Retinal Vein Occlusion Market.
The Retinal Vein Occlusion Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
At present, there is no treatment available to reverse Retinal Vein Occlusion. Most people with this condition will permanently change their vision, and the main goal of the available treatment is to stabilize vision by sealing off leaking blood vessels. However, several major pharma and biotech giants such as AbbVie, Roche, Regeneron Pharmaceuticals, Taiwan Liposome Company, Aerie Pharmaceuticals, Graybug Vision, Outlook Therapeutics, Kodiak Sciences Inc, Chugai Pharmaceuticals, and others are actively working in the therapeutic market.
The pipeline for RVO is dynamic, consisting of TLC399 (ProDex), AR1105, GB102, ONS-5010/Lytenava, Vabysmo, and KSI-301 in the late stages of development. Besides these, other therapies in the early stages include MHU650, ANXV, Autologous Bone Marrow CD34+ Stem Cells, and AXT107, among others.
Retinal Vein Occlusion Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for the treatment of Retinal Vein Occlusion and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Retinal Vein Occlusion market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
Retinal Vein Occlusion pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Oral
-
Parenteral
-
Intravitreal
-
Subretinal
-
Topical
Molecule Type
Products have been categorized under various Molecule types, such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Learn How the Ongoing Clinical & Commercial Activities will Affect the Retinal Vein Occlusion Therapeutic Segment @
https://www.delveinsight.com/sample-request/retinal-vein-occlusion-pipeline-insight
Retinal Vein Occlusion Therapeutics Landscape
Several major pharma and biotech companies are developing therapies for Retinal Vein Occlusion. Currently, Kodiak sciences are leading the therapeutics market with its Retinal Vein Occlusion drug candidates in the mid to advanced stage of clinical development.
The Leading Companies in the Retinal Vein Occlusion Therapeutics Market Include:
-
AbbVie
-
Aerie Pharmaceuticals
-
Allergan
-
Chugai Pharmaceuticals
-
Genentech
-
Graybug Vision
-
Kodiak Sciences
-
Kodiak Sciences Inc
-
Novartis Pharmaceuticals
-
Outlook Therapeutics
-
Regeneron Pharmaceuticals
-
Ripple Therapeutics
-
Roche
-
Sunshine Guojian Pharmaceutical
-
Taiwan Liposome Company
-
The Emmes Company
And Many Others
Retinal Vein Occlusion Emerging and Marketed Drugs Covered in the Report Include:
-
601: Sunshine Guojian Pharmaceutical
-
AR-1105: Aerie Pharmaceuticals
-
Eylea (aflibercept): Regeneron Pharmaceuticals
-
GB-102 (sunitinib/sunitinib malate): Graybug Vision
-
IBE-814: Ripple Therapeutics
-
KSI-301: Kodiak Sciences),
-
Lucentis intravitreal injection (ranibizumab): Genentech
-
ONS-5010/Lytenava(bevacizumab-vikg): Outlook Therapeutics
-
Ozurdex (dexamethasone): AbbVie
-
TLC399/ProDex: Taiwan Liposome Company
-
Vabysmo (faricimab/RG7716): Roche/ Chugai Pharmaceutical
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
https://www.delveinsight.com/sample-request/retinal-vein-occlusion-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Retinal Vein Occlusion Current Treatment Patterns
4. Retinal Vein Occlusion – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Retinal Vein Occlusion Late Stage Products (Phase-III)
7. Retinal Vein Occlusion Mid-Stage Products (Phase-II)
8. Retinal Vein Occlusion Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Retinal Vein Occlusion Discontinued Products
13. Retinal Vein Occlusion Product Profiles
14. Key Companies in the Retinal Vein Occlusion Market
15. Key Products in the Retinal Vein Occlusion Therapeutics Segment
16. Dormant and Discontinued Products
17. Retinal Vein Occlusion Unmet Needs
18. Retinal Vein Occlusion Future Perspectives
19. Retinal Vein Occlusion Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
https://www.delveinsight.com/sample-request/retinal-vein-occlusion-pipeline-insight
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/